NCT02141087 is a clinical trial of Pirfenidone in Idiopathic Pulmonary Fibrosis, sponsored by Genentech, Inc..

Who is sponsoring NCT02141087?

NCT02141087 is sponsored by Genentech, Inc..

What drugs are being tested in NCT02141087?

Interventions in NCT02141087: Pirfenidone.

What condition does NCT02141087 study?

NCT02141087 studies Idiopathic Pulmonary Fibrosis.

Is NCT02141087 still recruiting?

NCT02141087 is currently approved for marketing. Last updated 13 July 2015.

Last reviewed 2015-07-13 · How we verify

NCT02141087

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Expanded Access Program (EAP): Allow Patients in the US With Idiopathic Pulmonary Fibrosis Access to Pirfenidone

APPROVED FOR MARKETING Last updated 13 July 2015

What this trial tests

trial testing Pirfenidone in Idiopathic Pulmonary Fibrosis. Approved for marketing.

Quick facts

Lead sponsor	Genentech, Inc.
Status	APPROVED FOR MARKETING
Study type	EXPANDED_ACCESS

Drugs / interventions tested

Pirfenidone — full drug profile →

Conditions studied

Idiopathic Pulmonary Fibrosis — all drugs for Idiopathic Pulmonary Fibrosis →

Sponsor

Genentech, Inc. — full company profile →

Who can join

18 and older, any sex, with Idiopathic Pulmonary Fibrosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an open label multi-center program to allow patients in the US with IPF access to treatment with pirfenidone.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis.
Lancaster LH, de Andrade JA, Zibrak JD, Padilla ML, et al · · 2017 · cited 192× · PMID 29212837 · DOI 10.1183/16000617.0057-2017
Dose modification and dose intensity during treatment with pirfenidone: analysis of pooled data from three multinational phase III trials.
Nathan SD, Lancaster LH, Albera C, Glassberg MK, et al · · 2018 · cited 36× · PMID 30116539 · DOI 10.1136/bmjresp-2018-000323
Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis: Experience from 92 Sites in an Open-Label US Expanded Access Program.
Lancaster L, Morrison L, Auais A, Ding B, et al · · 2017 · cited 12× · PMID 32026347 · DOI 10.1007/s41030-017-0049-z

Verify or expand the search:

Other trials of Pirfenidone

Trials testing the same drug.

NCT06241560 — A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in · Phase 2 · recruiting
NCT07082842 — Confirmatory Clinical Study of HEC585 Tablets in Patients With IPF · Phase 3 · not yet recruiting
NCT07015398 — A Study of the Pharmacokinetic Interaction Between Pirfenidone, Nintedanib, and Nalbuphine Extended Release (NAL ER) in · Phase 1 · completed
NCT06485635 — Real-life-persistence to Antifibrotic Treatments · completed
NCT06484153 — Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Advanced or Metastatic pMMR/MSS Colorectal Carcin · Phase 1, PHASE2 · not yet recruiting

Other recruiting trials for Idiopathic Pulmonary Fibrosis

Currently open trials in the same condition.

NCT05988463 — Dose-Escalation Study of Artesunate Patients With IPF · Phase 1 · recruiting
NCT06241560 — A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in · Phase 2 · recruiting
NCT07407543 — A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SRN001 in Healthy Korean and Cauc · Phase 1 · recruiting
NCT07036523 — A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) · Phase 2 · recruiting
NCT07225296 — A Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics o · Phase 1 · recruiting

Other Genentech, Inc. trials

Trials by the same sponsor.

NCT06984341 — A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in P · Phase 1 · recruiting
NCT07448038 — A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vas · Phase 2 · recruiting
NCT07425522 — A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With D · Phase 1 · recruiting
NCT07342114 — A Dose-Escalation Study of RO7875913 in Healthy Participants · Phase 1 · recruiting
NCT07214662 — A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Gire · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02141087 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Genentech, Inc.
Last refreshed: 13 July 2015

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02141087.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing